Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Breast Neoplasms 32Central Nervous System Neoplasms 30Carcinoma, Non-Small-Cell Lung 28Lung Neoplasms 27Head and Neck Neoplasms 26Glioblastoma 25Leukemia 24Squamous Cell Carcinoma of Head and Neck 22Lymphoma 22Gliosarcoma 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Sarcoma 17Astrocytoma 17Burkitt Lymphoma 14Pancreatic Neoplasms 13Rectal Neoplasms 12Lymphoma, Large B-Cell, Diffuse 12Uterine Cervical Neoplasms 11Neuroblastoma 11Lymphoma, Follicular 10Adenocarcinoma of Lung 10Lymphoma, Non-Hodgkin 9Lymphoma, Large-Cell, Immunoblastic 9Leukemia, Myeloid, Acute 9Esophageal Neoplasms 9Brain Neoplasms 9Lymphoma, Mantle-Cell 8Lymphoma, B-Cell, Marginal Zone 8Laryngeal Neoplasms 8Hodgkin Disease 8

Interventions

pegaspargase 2merphos 2dexamethasone acetate 2dexamethasone 21-phosphate 2blinatumomab 2azathiopurine 2auricularum 2Vincristine 2N,N-dicyclohexyl-isoborneol-10-sulfonamide 2Methotrexate 2Mercaptopurine 2Dexamethasone 2Cytarabine 2Calcium Dobesilate 2Asparaginase 2prednylidene 1hydrocortisone hemisuccinate 1deltacortene 1calaspargase pegol 1asparaginase erwinia chrysanthemi recombinant 1Thioguanine 1Spinal Puncture 1Specimen Handling 1Radiotherapy, Conformal 1Radiotherapy 1Radiation 1Prednisone 1Prednisolone 1Nivolumab 1Methylprednisolone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Down Syndrome × Radiotherapy × Clear all
NCT03914625 2026-05-27

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
6,720 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡